Telix Pharmaceuticals (NASDAQ:TLX) Upgraded at Royal Bank Of Canada

Royal Bank Of Canada upgraded shares of Telix Pharmaceuticals (NASDAQ:TLX) from a hold rating to a moderate buy rating in a report published on Monday,Zacks reports.

Other research analysts have also issued reports about the company. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Telix Pharmaceuticals in a report on Tuesday, September 15th. Wedbush reaffirmed an “outperform” rating and issued a $22.00 price target on shares of Telix Pharmaceuticals in a research report on Monday, September 14th. Citigroup reiterated a “buy” rating on shares of Telix Pharmaceuticals in a research note on Thursday, August 20th. Finally, Weiss Ratings raised Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a research report on Friday, August 21st. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $20.50.

Telix Pharmaceuticals Stock Performance

Telix Pharmaceuticals stock opened at $11.27 on Monday. Telix Pharmaceuticals has a twelve month low of $6.28 and a twelve month high of $13.11. The stock’s fifty day simple moving average is $11.32 and its 200-day simple moving average is $10.44. The company has a quick ratio of 1.85, a current ratio of 2.01 and a debt-to-equity ratio of 1.16.

Hedge Funds Weigh In On Telix Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. Hennion & Walsh Asset Management Inc. acquired a new stake in shares of Telix Pharmaceuticals during the 2nd quarter worth about $1,731,000. Private Advisor Group LLC boosted its holdings in Telix Pharmaceuticals by 276.3% in the first quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock valued at $1,669,000 after purchasing an additional 128,070 shares in the last quarter. XY Capital Ltd boosted its holdings in Telix Pharmaceuticals by 468.0% in the second quarter. XY Capital Ltd now owns 71,291 shares of the company’s stock valued at $822,000 after purchasing an additional 58,739 shares in the last quarter. Bank of America Corp DE boosted its holdings in Telix Pharmaceuticals by 523.8% in the first quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock valued at $96,000 after purchasing an additional 8,423 shares in the last quarter. Finally, Lazard Asset Management LLC increased its stake in Telix Pharmaceuticals by 15.7% in the first quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock valued at $2,775,000 after purchasing an additional 39,400 shares during the last quarter.

Trending Headlines about Telix Pharmaceuticals

Here are the key news stories impacting Telix Pharmaceuticals this week:

• Positive Sentiment: Analyst support strengthened: Wedbush reaffirmed its “outperform” rating and set a $22.00 price target, implying substantial potential upside from current levels. RBC also upgraded Telix from “hold” to “moderate buy,” signaling improving confidence in the company’s outlook. Wedbush rating RBC upgrade
• Positive Sentiment: $2.35 billion ITM acquisition: Telix agreed to acquire Germany’s ITM Isotope Technologies Munich for $1.65 billion upfront, with up to another $700 million tied to regulatory approval and sales milestones. The transaction is intended to secure cancer-isotope supply, expand Telix’s radiopharmaceutical reach and strengthen its oncology platform. ITM acquisition details
• Neutral Sentiment: Strategic and pipeline updates: Telix’s research and development presentation, transcript and merger call highlighted its oncology pipeline and strategic rationale for the ITM transaction. The longer-term opportunity depends on successful development, regulatory approvals and commercial execution. R&D Day transcript
• Negative Sentiment: Financing and execution risk: The acquisition’s large size, including consideration paid primarily in Telix shares, raises dilution concerns and leaves investors focused on integration, funding and the risk that ITM’s lead product fails to achieve approval or sales milestones. Coverage has specifically questioned whether the isotope takeover contributed to Telix’s recent share weakness. Takeover and share weakness

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals for the diagnosis and treatment of cancer and other serious diseases. Its products use targeted molecules to deliver radioactive isotopes to specific tissues, supporting precision imaging and therapeutic applications.

The company’s commercial portfolio includes Illuccix, a gallium-68 radiolabeled prostate-specific membrane antigen (PSMA) imaging agent used with PET scans to help detect and manage prostate cancer.